ADVERTISEMENT

Are HMAS appropriate for posttransplant maintenance in acute leukemias?

Randy Dotinga   |   Conference Report   |   05 November 2020
ADVERTISEMENT

FROM ALF 2020

Hematopoietic stem cell transplantation (HCT) is one of the most important treatment options for acute leukemias. However, posttransplant cancer recurrence remains a continuing issue. And while there are reasons to think that hypomethylating agents (HMAS) could be helpful as maintenance tools to prevent cancer recurrence after HCT...

          

Topic Challenges

left
right